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Cardiac tumorsrepresent arelatively rare, yet challenging diagnosis.Secondarytumors are farmore frequent than primarytumors
of the heart. The majority of primary cardiac tumors is benign in origin, with primary malignant tumors accounting for 25%
of cases. Metastatic tumors usually arise from lung, breast, renal cancer, melanomas, and lymphomas. Clinical manifestations of
cardiactumorsdepend onthesizeandlocationofthemassandtheinﬁltrationofadjacenttissuesratherthanthetypeofthetumor
itself. Echocardiography is the main diagnostic tool for the detection of a cardiac mass. Other imaging modalities (C-MRI, C-CT,
3D Echo) may oﬀer further diagnostic informationand the establishment of the diagnosis is made with histologicalexamination.
Managementdepends on the type of the tumor and the symptomatology of the patient.
1.Introduction
Cardiac tumors are a challenging and bizarre clinical situ-
ation. They are diﬀerentiated into primary and secondary
(metastatic). The prevalence of primary cardiac tumors is
0.001–0.03% in autopsy series [1]. Seventy-ﬁve per cent of
primary tumors are benign in origin, with myxoma being
the most frequent over 50% of cases. From the remaining
25% of malignant cardiac tumors, most frequent are cardiac
sarcomas. Secondary tumors are from 20- to 40-fold more
commonthanprimarytumors,and15%ofpatientssuﬀering
from any form of cancer exhibit metastases in the heart.
2.Classiﬁcation
2.1. Primary Cardiac Tumors
2.1.1. Benign Tumors
Myxoma. Myxoma represents the most frequent benign
tumor in adult population [2]. It accounts for 25% of all
cardiac tumors, more than 50% of benign cardiac tumors,
and it aﬀects mainly women and age groups of 30 to 60 years
old. Myxomas are thought to originate in undiﬀerentiated
and totipotent mesenchymal stem cells [3]. Seventy-ﬁve per
cent of myxomas are located in the left atrium (arising from
the fossa ovalis of the interatrial septum), 20% in the right
atrium and the remaining 5% in the ventricles. Myxomas
usuallyhaveanarrowbaseofattachment(pedicle)tothecar-
diac wall and their composition is heterogeneous, consisting
of areas with hemorrhage, necrosis, cyst formation, ﬁbrosis,
and calciﬁcation. In approximately 7% of cases, myxomas
are familial, with most pronounced case being the Carney
complex.This syndrome isan autosomaldominantinherited
disease, where multiple myxomas, extracardial myxomas
(breast, skin), schwannomas, abnormal skin pigmentation
and endocrine overactivityorendocrine tumors, may coexist
[4]. In cases of atrial myxomas in the setting of the Carney
complex, relapses are frequent, and close monitoring of the
patients is essential.
Lipomas and Lipomatous Hypertrophy of the Interatrial Sep-
tum. Lipomas represent the second most frequent primary
tumor, and they are usually located in the subepicardium,
in the left ventricle, the right atrium, and the interatrial
septum. Often they are asymptomatic; however, they may
cause arrhythmias, conduction system disturbances, and
symptoms of heart failure, especially in cases where they2 ISRN Oncology
reach a large size [5]. Lipomatous hypertrophy of the
interatrial septum is the result of hyperplasia and the accu-
mulation of adipose tissue on the interatrial septum (except
for the fossa ovalis area), and it aﬀects mainly the elderly and
o b e s em a l ep a t i e n t s[ 6].
Papillary Fibroelastoma. Papillary ﬁbroelastoma is the most
common tumor of the cardiac valves, accounting for 75% of
valvular tumors. Papillary ﬁbroelastoma usually aﬀects the
elderly (age range 60 ± 16) [7]. It is generally small in size
(<1cm),anditaﬀects mainly the aortic or the mitral valve,
even though tricuspid and pulmonary valves may also be
aﬀected [8].
Rhabdomyoma. Rhabdomyoma represents the most com-
mon cardiac tumor in children. Rhabdomyomas are usually
multiple, and they aﬀect the right and the left ventricle
likewise. They may cause mechanical complications, such as
obstruction of the right ventricular outﬂow tract. It is also
common for rhabdomyomas to regress spontaneously after
birth [9].
Fibroma. Fibroma is the second most common cardiac
tumor of childhood, although it may also aﬀect the adult
population. Fibromas are intramural tumors, located in the
left ventricle, mainly in the intraventricular septum, and
they are often mistaken for hypertrophic cardiomyopathy or
apical thrombus.
Other Primary Benign Tumors. Angiomas, teratomas, and
mesotheliomasareraretumors(accountingfor7%ofcardiac
tumors), and they aﬀect mainly children. Teratomas are
located in the pericardium, and they may lead to constrictive
pericarditis.
2.1.2. Malignant Tumors. Primary malignant tumors are
relatively rare (accounting for 25% of primary cardiac
tumors); they aﬀe c ta g e sf r o m3 0t o5 0y e a r so l d ,a n dt h e y
are usually sarcomas (angiosarcoma, rhabdomyosarcoma,
leiomyosarcoma, liposarcoma, osteosarcoma, ﬁbrosarcoma,
and malignant ﬁbrous histiocytoma). Most angiosarcomas
are usually located in the right chambers of the heart [10],
whereasothersarcomasaﬀecttheleftatriummorefrequently
[11]. Malignant tumors confer a poor prognosis by exten-
sively inﬁltrating the myocardium, causing obstruction of
intracardial ﬂow and producing metastases.
2.2. Secondary (Metastatic) Cardiac Tumors. Metastatic car-
diac tumours are far more frequent (approximately from 30-
to 40-fold) than primary tumors of the heart [12]. They
usually arise from melanomas, lung,breast, and renal cancer,
as well as lymphomas. Metastases may originate from blood
dissemination of cancer cells, direct extension via adjacent
tissues, or propagation via the superior or the inferior vena
cava to the right atrium. Pericardium is most often aﬀected,
resulting in pericardial eﬀusion which may contain masses
comprising either cancer cells or blood clots and ﬁbrin.
The “carcinoid syndrome” leads to lesions usually in the
right heart chambers. It aﬀects mainly the cardiac valves
with deposition of ﬁbrous plaques, leading to thickening,
shortening, and motion restraint of the tricuspid and/or the
pulmonic valve and subsequent regurgitation or stenosis of
these valves.
3.Diagnostic Evaluation(Figure1)
Diagnosis and diﬀerential diagnosis of cardiac tumors often
presents a challenge for the physician. Cardiac tumors, either
benignormalignant,arediﬃculttobediagnosedduetotheir
rarity, variety, and nonspeciﬁcity of the symptoms that they
may cause. Patient’s history, clinical examination, and blood
tests rarely lead to an immediate diagnosis of the tumor;
therefore,suspicionofthisconditioniscriticalforthecorrect
and timely diagnosis of a cardiac tumor. Furthermore,
beyond the performance of imaging techniques (discussed
below), histological evaluation via biopsy is essential for the
ﬁnal diagnosis to be established.
3.1. Clinical Manifestations. Clinical manifestations of car-
diac tumors are diﬀerentiated in to four categories: system-
atic manifestations, embolic events, cardiac manifestations,
and ﬁnally manifestations due to metastases.
The systematic symptoms and laboratory ﬁndings may
resemble those of vasculitis and connective tissue diseases
and may disorientate from the correct diagnosis. Fever may
be present, as well as fatigue, arthralgia, rush, and the Ray-
naud phenomenon. The laboratory tests may reveal anemia,
elevated white blood cell count and platelet count, thrombo-
cytopenia, hypergammaglobulinemia, and elevated erythro-
cyte sedimentation rate (ESR). Systematic manifestations are
attributedtosecretion ofvariousfactors from thetumorcells
(Interleukin 6, Endothelin).
Cardiac tumors may be the cause of pulmonary embolism
or peripheral embolism due to the embolism of tumor cells
or thrombi formed on the tumor surface. Predisposition to
embolic episodes depends mainly on the type of the tumor,
its location (intramural or intracardial), and the fragility of
its surface. Small tumors with a friable appearance have a
higher chance of embolization.
Regarding cardiac manifestations, these depend mainly
on the anatomic location, the size of the tumor, and the
inﬁltration of adjacent tissues, rather than the histological
type of the tumor. Cardiac manifestations may be caused by
direct obstruction of cardiac or valve function, interruption
of coronary ﬂow, interpolation on the electrophysiology of
myocardial contraction, and induction of pericardial eﬀu-
sion.Intramuraltumorsrarelyproducesymptoms,especially
if their size is small. They may cause arrhythmias or distur-
bance ofthe conductionsystem, and in cases of large tumors,
they may cause obstruction of the right or left outﬂow tract
orcompression ofthecardiac chambers. Intracardiac tumors
may exert severe clinical manifestations. Characteristically,
myxomas of the left atrium may cause symptoms of mitral
obstruction through prolapse via the mitral valve (syncope
depending on change of patient’s position, dyspnoea, etc.).ISRN Oncology 3
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Figure 1: Algorithm for the detection and diﬀerential diagnosis of a cardiac tumor. TTE: Transthoracic echocardiography, TEE:
Transesophageal echocardiography, 3D Echo: Three dimensional echocardiography, C-MRI: cardiac magnetic resonance, C-CT: Cardiac
computed tomography.
Tumors located in the right chambers of the heart may cause
signs and symptoms of right-sided heart failure.
Regarding cardiac manifestations due to metastatic dis-
ease from other organs, these usually aﬀect the pericardium
(55%, pericardial eﬀusion, cardiac tamponade, or constrict-
ive pericarditis) and less often the myocardium, the endo-
cardium (heart failure, arrhythmias), and the venae cavae
(obstruction). In general, the presentation of cardiac man-
ifestation in a patient suﬀering from cancer is usually at-
tributed either to cardiotoxicity because of chemotherapy
[13] or occurrence of cardiac metastases.
Finally, primary cardiac tumors can cause symptoms
through metastases to other organs. Most frequently, sarco-
mas metastases aﬀect lungs, brain, and bones.
3.2. Imaging Techniques. The imaging techniques that are
used when there is a suspicion for the occurrence of a
c a r d i a ct u m o r ,a sw e l la sf o rt h ed i ﬀerential diagnosis of
othercardiacmasseslikevegetationsandthrombi,aremainly
echocardiography, magnetic resonance imaging (MRI), and
computed tomography (CT) of the heart. Chest X-ray can
oﬀer indirect ﬁndings from the enlargement of cardiac
chambers, the occurrence of calciﬁcation, or pericardial
eﬀusion.
3.2.1. Echocardiography. Echocardiography represents a sub-
stantial imaging technique for the detection of cardiac
tumors with ahigh sensitivity and speciﬁcity (90% and 95%,
resp.), and it can be easily performed at the patient’s bedside
[14]. Transthoracic echocardiography (TTE) can depict the
shape, the size, the extent, and the mobility of the tumor,
as well as, its location and its relation to adjacent cardiac
structures, the width of adherence to the cardiac wall, and
the hemodynamic consequencesthat itmay conferto cardiac
function [15]. Transesophageal echocardiography (TEE) is
superior to TTE, since one can avoid transducer contact
with the thoracic wall and the lungs and achieve a better
visualization and identiﬁcation of small tumors (<5 mm)
and tumors localized at the posterior cardiac segments [16].
It should be performed when there is a low quality of TTE4 ISRN Oncology
image due to poor acoustic window or when serious clinical
questionsregarding thenatureofamassremainunanswered.
However, the echo ﬁeld remains narrow and no information
regarding the composition and the perfusion of a mass is
given.
Of interest are newer echocardiographic techniques that
may aid in the diﬀerential diagnosis of cardiac tumors from
other cardiac masses. Contrast echocardiography helps in
the diﬀerential diagnosis between tumor and thrombus by
examining tissue perfusion [17]. In contrast to thrombi,
malignant tumors or tumors rich in vascularity, in general,
appear with an intense enhancement of the echocardio-
graphic image when contrast medium is administered, and
therefore, contrast echo leads to an accurate diagnosis.
Benign cardiac tumors (i.e., myxomas) exhibit sparse vascu-
larity, and medium enhancement of the echocardiographic
signal appears sometimes even lower to that of proximal
myocardium. Therefore, because of their sparse vascularity,
the diﬀerential diagnosis between myxomas and thrombi,
with the use of contrast echocardiography, is less reliable in
comparison to malignant tumors [18].
Three-dimensional echocardiography (3D Echo) con-
tributes mainly to an improved assessment of the shape, the
size, the mobility of a tumor and its relationship regarding
adjacent structures, by making use of the wider imaging
range that this technique provides [19]. Improvement of this
technique in order to provide better temporal and spatial
resolution is expected in the near future.
3.2.2. Magnetic Resonance. The use of cardiac magnetic
resonance (C-MRI) with its wide imaging range allows for
a better assessment of the tumor relation to adjacent struc-
tures, in order for a surgical resection technique to be
designed. It also allows the detection of myocardial inﬁl-
tration by the tumor or expansion of the mass to the
pericardium or to adjacent structures [20]. C-MRI may also
contribute to the characterization of the composition of the
tumorbystudying thesignal inT1-and T2-weighted images,
as well as the enhancement of the signal after gadolinium
administration. Recent technologic advances in cardiac MRI
have resulted in the rapid acquisition of images of the heart
with high spatial and temporal resolution and excellent
myocardial tissue characterization [21]. Administration of
contrast medium helps diﬀerentiate a cardiac tumor from
thrombus formation or blood ﬂow artifacts [22].
3.2.3. Computed Tomography. Cardiac computed tomog-
raphy (C-CT) can also provide useful information, due
to its high resolution and its ability to accurately depict
cardiac morphology without limitations because of acoustic
windows. Disadvantages of the method include the use
of radioactivity and of nephrotoxic contrast mediums. C-
CT provides less information regarding characterization of
tissues in comparison to C-MRI; however, it can provide
some information regarding the nature of the tumor by
measuring X-ray attenuation and possible tumor expansion
to adjacent tissues. Multidetector computed tomography
(MDCT) is useful for the evaluation of calciﬁcation and
fat content within a mass. Furthermore, the high spatial
resolution of MDCT is beneﬁcial to deﬁne small lesions,
making this technique a useful tool for the staging of
malignant tumors [23].
3.3. Histological Evaluation. The diagnosis of cardiac tumors
and the estimation of their grade cannot be made with
the use of imaging methods only, therefore histological
conﬁrmation is necessary. This can be achieved with min-
imally invasive techniques such as cytological examination
of pericardial or pleural ﬂuid or echocardiographically aided
percutaneous or transvenous cardiac biopsy. In cases where
diagnosis cannot be established, biopsy via thoracoscopy or
even thoracotomy may be needed.
4.Management
Therapy of benign primary cardiac tumors is surgical
resection, and the urgency to intervene is determined by
the symptoms of the patient and the type of the tumor.
Regarding myxomas, immediate surgical resection is indi-
cated, regardless of symptoms, because of the high risk of
embolic and cardiac complications. Surgical resection of
myxomas confersgoodresults(3%possibility ofrelapse)and
is accompanied with small rates of periprocedural mortality
(<5%). Papillary ﬁbroelastomas are surgically removed in
cases of large (>1cm) and/or mobile tumors. In cases of
small, immobile tumors in the left ventricles, conservative
management and close follow-up may be advocated. How-
ever, because of their fragile nature, papillary ﬁbroelastomas
carry a high risk of embolic complications; therefore, most
authors propose surgical management evenin asymptomatic
patients [24]. Lipomas and lipomatous hypertrophy of the
interatrial septum are surgically managed only in cases of
serious hemodynamic compromise. Rhabdomyomas usually
do not require surgical management, since they tend to
regress spontaneously.
Regardingmalignantprimary cardiactumors,theirprog-
nosis is dismal, since they tend to inﬁltrate the myocardium
rapidly, cause obstruction of the cardiac chambers and
produce metastases. Management of choice in sarcomas
is surgical resection, with poor results and high rates of
relapse [25]. Chemotherapy is used as an adjuvant to help
decrease tumor size and facilitate surgical resection, or in
cases of nonoperable or metastatic sarcomas. In spite of
the aforementioned therapeutic attempts the survival rate
in cases of sarcomas does not usually exceed one year. In
cardiac lymphomas, systematic chemotherapy with or with-
out radiotherapy is usually undertaken.
Finally, regarding cardiac manifestations due to meta-
static extracardiac cancer, priority is given to the manage-
ment of the primary focus of the disease and the cardiovas-
cular complications that are manifested (i.e., percutaneous
balloon pericardiotomy in cases of cardiac tamponade,
radiotherapy and chemotherapy in cases of tumors that
obstruct ﬂow in the venae cavae, etc.).ISRN Oncology 5
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